


## ASX Announcement

# RECCE® 327 Registered in the Australian New Zealand Clinical Trials Registry for Phase I/II Topical Burns Study in Humans

**Sydney Australia, 15 April 2021:** Recce Pharmaceuticals Ltd (**ASX:RCE**) (**FSE:R9Q**), is pleased to announce its lead compound RECCE® 327 (R327) has been registered in the Australian New Zealand Clinical Trial Registry (ANZCTR) for its Phase I/II Topical Burns Study in Humans under the Trial ID ACTRN12621000412831.



The screenshot shows the ANZCTR (Australian New Zealand Clinical Trials Registry) website. The header includes the ANZCTR logo and navigation links: FAQs, HOW TO GET INVOLVED, NEWS, and ABOUT US. There are also buttons for CREATE ACCOUNT and LOGIN. The main content area displays the trial registration details for RECCE® 327. It includes a 'Trial from ANZCTR' section with a 'View full record' link and a 'Select for download' checkbox. The trial title is 'Proof of concept study of RECCE® 327 topical antibiotic therapy for infected burn wounds in adults'. Below the title, there are four status indicators: 'Not yet recruiting', 'Ethics status: Approved', 'Prospectively registered', and 'Up to date (Last updated: 15/4/2021)'. At the bottom, there are three expandable sections: 'Key trial Information', 'Eligibility', and 'Contact details and further information'.

The ANZCTR is an online registry of clinical trials being undertaken in Australia, New Zealand and elsewhere. The ANZCTR includes trials from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies. This registration represents one of the final administrative stages for the clinical trial to commence.

The Company's clinical trial is registered under '*Proof of Concept Study of RECCE 327 Topical Antibiotic Therapy for Infected Burn Wounds in Adults*' and involves 30 patients to assess safety and efficacy of R327. Over 14 days, 10 patients will receive R327 daily while a further 20 receive treatment three times per week. The Company looks forward to updating shareholders on the progression of this trial over the time ahead.

This announcement has been approved for release by Recce Pharmaceuticals Chairman.



**ASX:** RCE

**Head Office:** Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE® 327, RECCE® 435, and RECCE® 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE® 435, has been formulated for oral use.

The FDA has awarded RECCE® 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts *Global New Antibiotics in Development Pipeline* as the only synthetic polymer drug candidate for treating sepsis currently in development.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.



### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
+61 (02) 9256 2571  
james.graham@recce.com.au

### Media and Investor Relations (AU)

Andrew Geddes  
CityPR  
+61 (02) 9267 4511  
ageddes@citypublicrelations.com.au

### Media and Investor Relations (USA)

Meredith Sosulski, PhD  
LifeSci Communications  
+1 929 469 3851  
msosulski@lifescicomms.com

**recce.com.au**  
ACN 124 849 065